Home
NewsNewsIndia's Central Drugs Standard Control Organisation has overhauled CDSCO IVF reagent sale norms, directing that all ART media, culture solutions, and reagents be supplied exclusively to clinics registered under the ART (Regulation) Act and Surrogacy (Regulation) Act. The move targets a growing unlicensed supply chain feeding an estimated 40–50% of India's 2,000-plus IVF centres.
India's drug regulatory authority has reinforced compliance requirements for the sale and distribution of assisted reproductive technology (ART) products, directing stakeholders to supply IVF media, reagents, and related products only to centres registered under the country's ART and surrogacy laws. The move strengthens CDSCO IVF Reagent Sale Norms aimed at ensuring patient safety and preventing the misuse of reproductive technologies.
In a recent regulatory communication, the Central Drugs Standard Control Organisation (CDSCO) stated that all medical devices, including media, reagents, and other products used in assisted reproductive procedures such as in-vitro fertilisation (IVF) and cryopreservation, are regulated under the Medical Devices Rules, 2017. Manufacturers and importers of these products are required to obtain the necessary licences to ensure the quality, safety, and performance of the devices.
According to the regulator, these products are intended for use by ART clinics and banks that are registered under the Assisted Reproductive Technology (Regulation) Act, 2021, and the Surrogacy (Regulation) Act, 2021. These laws were introduced to promote the safe, ethical, and regulated delivery of reproductive healthcare services across India.
The regulator noted that it has come to its attention that IVF media and related products are being supplied to facilities that are not registered under the applicable legislation. Such practices, CDSCO warned, could increase the risk of misuse of assisted reproductive technologies and potentially compromise patient health and welfare.
To address these concerns, the authority has urged manufacturers, importers, distributors, and other stakeholders to ensure that the supply of ART media and reagents is limited exclusively to centres registered under the ART and Surrogacy Acts. The updated CDSCO IVF Reagent Sale Norms are intended to strengthen regulatory oversight while supporting ethical reproductive healthcare practices nationwide.
The latest directive further aligns the regulation of reproductive technology products with India's broader medical device framework, reinforcing traceability and accountability throughout the supply chain. By tightening CDSCO IVF Reagent Sale Norms, the regulator aims to ensure that sensitive reproductive products remain accessible only to authorised facilities operating within the country's legal and ethical framework.
Pulsenmore has completed MHRA registration of Pulsenmore FC, entering the UK fertility market with its patient-operated home ultrasound system for follicular and endometrial monitoring during IVF and fertility preservation treatments. The move follows CE European registration and targets a UK market where over 100,000 fertility treatment cycles were performed in 2024.
Memphasys has confirmed a Felix System Nordic expansion into Denmark, Sweden, Norway, Finland, and Iceland through an exclusive agreement with fertility-technology distributor NOVIVITAE ApS. The deal carries minimum contracted purchases of €526,500 across three years, with an initial order of €20,625 and three Felix™ consoles to be supplied in the September 2026 quarter.
Abu Dhabi University and FertiClinic Group have joined forces to establish the FertiClinic Reproductive Research Lab, an advanced reproductive research lab in Abu Dhabi housing IVF, andrology, and cryopreservation facilities. The partnership supports UAE national priorities, bridges academic and clinical expertise, and advances fertility innovation across the region.
NHS Kent and Medway has overhauled its fertility funding policy in a move that sees NHS cuts IVF access for thousands of patients. Effective 1 April 2026, the eligible age ceiling drops from 40 to 38, funded cycles fall from two to one, and embryo transfers are capped at two.
ASEAN's First Telemedicine IVF by Inspire IVF introduces a new era of remote fertility care. Combining AI technology with expert consultation, the platform enables global access, real-time monitoring, and personalised treatment planning, positioning Thailand as a leading hub for fertility services and advancing digital transformation in reproductive healthcare.
CSG.BIO has gone ahead with the acquisition of Hanabusa IVF, Asian Egg Bank, thereby making it a world leader in reproductive medicine and cutting-edge clinics with enhanced patient reach and advanced laboratory capabilities.
